The Munich Deeptech startup Hemato is developing a cloud-based AI platform for analyzing blood samples. The technology enables faster and more precise diagnostics of blood cancers and immune disorders. Previously, the analysis was performed manually by specialists and took approximately 20 minutes per sample. Hemato's solution aims to reduce this time to one minute and significantly reduce false-negative results.
Karsten Miermans, CEO and co-founder of Hemato, emphasizes the importance of the financing round:
"Our goal is to bring AI-supported precision diagnostics to immunomedicine, to relieve the often overworked staff in clinical laboratories, and to enable the right treatment at the right time for every patient."
Investors attest to Hemato’s great market potential
The financing round was led by Lumo Labs. In addition to Bayern Kapital, Cross Atlantic Angels and existing investors such as Elaia, Heal Capital, High-Tech Gründerfonds (HTGF), and Becker Ventures participated. The company plans to use the funds to further develop its AI-supported diagnostic solution and accelerate its market entry.
Monika Steger, Managing Director of Bayern Kapital, says:
"With hema.to's AI-powered analysis platform, blood data analysis time can be reduced to a fraction of the usual manual time. This not only relieves the burden on clinical laboratories and promotes patient well-being, but also addresses a multi-billion dollar global market."
Also Sven Bakkes, partner of Lumo Labs, sees great opportunities:
"We are delighted to welcome Hemato to our portfolio. Their AI-powered platform analyzes raw cytometry data in seconds and detects more diseases than manual analysis—soon even in early stages. For clinicians, this represents a dramatic time saving. For patients, it can make the critical difference between a missed disease and life-saving early intervention."
Currently the Analysis platform Hemato's technology is already being used in initial clinical laboratories and hospitals. In the future, the solution's analytical capabilities will be expanded beyond blood cancer to include other clinical conditions, particularly other autoimmune diseases. Additional applications, such as clinical trials and therapy monitoring, are also planned.
